High expression of GPER1, EGFR and CXCR1 is associated with lymph node metastasis in papillary thyroid carcinoma

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 6, 2014, Pages 3213-3223

  Tang, Cui ^a   Yang, Lei ^a   Wang, Ni ^a   Li, Li ^a   Xu, Man ^a   Chen, George G ^b   Liu, Zhi Min ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

CXCR1; EGFR; GPER1; Papillary thyroid carcinoma

Indexed keywords

CHEMOKINE RECEPTOR CXCR1; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR; GPER PROTEIN, HUMAN; TUMOR MARKER;

ADULT; BIOSYNTHESIS; CARCINOMA; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID TUMOR; TISSUE MICROARRAY; UPREGULATION;

ADULT; CARCINOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, INTERLEUKIN-8A; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THYROID NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84904360941     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Rahbari R, Zhang L and Kebebew E. Thyroid cancer gender disparity. Future Oncol 2010; 6: 1771-1779.
2. Persson I, Yuen J, Bergkvist L and Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy--long-term follow-up of a Swedish cohort. Int J Cancer 1996; 67: 327-332.
3. Pike MC, Pearce CL and Wu AH. Prevention of cancers of the breast, endometrium and ovary. Oncogene 2004; 23: 6379-6391.
4. Revankar CM, Cimino DF, Sklar LA, Arterburn JB and Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005; 307: 1625-1630.
5. Filardo EJ, Quinn JA, Bland KI and Frackelton AR Jr. Estrogen-Induced Activation of Erk-1 and Erk-2 Requires the G Protein-Coupled Receptor Homolog, GPR30, and Occurs via Trans-Activation of the Epidermal Growth Factor Receptor through Release of HB-EGF. Mol Endocrinol 2000; 14: 1649-1660.
6. Prossnitz ER, Sklar LA, Oprea TI and Arterburn JB. GPR30: a novel therapeutic target in estrogen-related disease. Trends Pharmacol Sci 2008; 29: 116-123.
7. Lappano R, De Marco P, De Francesco EM, Chimento A, Pezzi V and Maggiolini M. Cross-talk between GPER and growth factor signaling. J Steroid Biochem Mol Biol 2013; 137: 50-56.
8. Filardo EJ, Graeber CT, Quinn JA, Resnick MB, Giri D, DeLellis RA, Steinhoff MM and Sabo E. Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin Cancer Res 2006; 12: 6359-6366.
9. Smith HO, Leslie KK, Singh M, Qualls CR, Revankar CM, Joste NE and Prossnitz ER. GPR30: a novel indicator of poor survival for endometrial carcinoma. Am J Obstet Gynecol 2007; 196: 386, e1-386, e9.
10. Smith HO, Arias-Pulido H, Kuo DY, Howard T, Qualls CR, Lee SJ, Verschraegen CF, Hathaway HJ, Joste NE and Prossnitz ER. GPR30 predicts poor survival for ovarian cancer. Gynecol Oncol 2009; 114: 465-471.
11. Mitrasinovic PM. Epidermal growth factor receptors: a functional perspective. Curr Radiopharm 2012; 5: 29-33.
12. Nedergaard MK, Hedegaard CJ and Poulsen HS. Targeting the epidermal growth factor receptor in solid tumor malignancies. Bio Drugs 2012; 26: 83-99.
13. Filardo EJ. Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer. J Steroid Biochem Mol Biol 2002; 80: 231-238.
14. Viale G, Rotmensz N, Maisonneuve P, Bottiglieri L, Montagna E, Luini A, Veronesi P, Intra M, Torrisi R, Cardillo A, Campagnoli E, Goldhirsch A and Colleoni M. Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat 2009; 116: 317-328.
15. Ozawa S, Ueda M, Ando N, Shimizu N and Abe O. Prognostic significance of epidermal growth factor receptor in esophageal squamous cell carcinomas. Cancer 1989; 63: 2169-2173.
16. Fisher KE, Jani JC, Fisher SB, Foulks C, Hill CE, Weber CJ, Cohen C and Sharma J. Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma. J Surg Res 2013; 185: 217-224.
17. Holmes WE, Lee J, Kuang WJ, Rice GC and Wood WI. Structure and functional expression of a human interleukin-8 receptor. Science 1991; 253: 1278-1280.
18. Jiang QF, Wu TT, Yang JY, Dong CR, Wang N, Liu XH and Liu ZM. 17β-estradiol promotes the invasion and migration of nuclear estrogen receptor-negative breast cancer cells through cross-talk between GPER1 and CXCR1. J Steroid Biochem Mol Biol 2013; 138: 314-324.
19. Waugh DJ and Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008; 14: 6735-6741.
20. Lang BH, Lo CY, Chan WF, Lam KY and Wan KY. Staging systems for papillary thyroid carcinoma: a review and comparison. Ann Surg 2007; 245: 366-378.
21. Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G and Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-847.
22. Livak KJ and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) Method. Methods 2001; 25: 402-408.
23. Matthews J and Gustafsson JA. Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol Interv 2003; 3: 281-292.
24. Prossnitz ER and Barton M. The G-protein-coupled estrogen receptor GPER in health and disease. Nat Rev Endocrinol 2011; 7: 715-726.
25. Fang W, Ye L, Shen L, Cai J, Huang F, Wei Q, Fei X, Chen X, Guan H, Wang W, Li X and Ning G. Tumor-associated macrophages promote the metastatic potential of thyroid papillary cancer by releasing CXCL8. Carcinogenesis 2014; [Epub ahead of print].
26. Konturek A, Barczyński M, Cichoń S, Pituch-Noworolska A, Jonkisz J and Cichoń W. Significance of vascular endothelial growth factor and epidermal growth factor in development of papillary thyroid cancer. Langenbecks Arch Surg 2005; 390: 216-221.
27. Vivacqua A, Lappano R, De Marco P, Sisci D, Aquila S, De Amicis F, Fuqua SA, Andò S and Maggiolini M. G protein-coupled receptor 30 expression is up-regulated by EGF and TGF alpha in estrogen receptor alpha-positive cancer cells. Mol Endocrinol 2009; 23: 1815-1826.
28. Albanito L, Sisci D, Aquila S, Brunelli E, Vivacqua A, Madeo A, Lappano R, Pandey DP, Picard D, Mauro L, Andò S and Maggiolini M. Epidermal growth factor induces G protein-coupled receptor 30 expression in estrogen receptor-negative breast cancer cells. Endocrinology 2008; 149: 3799-3808.
29. Filardo EJ and Thomas P. GPR30: a seven-transmembrane-spanning estrogen receptor that triggers EGF release. Trends Endocrinol Metab 2005; 16: 362-367.
30. Raychaudhuri B and Vogelbaum MA. IL-8 is a mediator of NF-κB induced invasion by gliomas. J Neurooncol 2011; 101: 227-235.
31. Maxwell PJ, Gallagher R, Seaton A, Wilson C, Scullin P, Pettigrew J, Stratford IJ, Williams KJ, Johnston PG and Waugh DJ. HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells. Oncogene 2007; 26: 7333-7345.